Quantumzyme Corp. Achieves Compliance Milestone with OTC Markets Group

Quantumzyme Corp. (OTC: QTZM), a biotechnology company focused on computational enzyme engineering, has reached a pivotal regulatory milestone with the OTC Markets Group removing its 'Caveat Emptor' designation. This reclassification to a Current Information issuer with a Verified Profile underscores the company's adherence to the OTCID disclosure framework, reflecting its commitment to transparency and regulatory compliance.

The removal of the 'Caveat Emptor' label comes after Quantumzyme implemented enhanced disclosure practices, including the submission of updated financial reports and the adoption of measures to improve corporate transparency. Additionally, the company has engaged securities counsel to ensure ongoing compliance with regulatory requirements. Naveen Kulkarni, CEO of Quantumzyme, highlighted the significance of this development, noting it enables the company to concentrate on advancing its business strategy and enhancing shareholder value.

Quantumzyme also took the opportunity to address previous unauthorized promotional activities, distancing itself from such actions and affirming its cooperation with any related investigations. The company's proactive stance on these issues further demonstrates its dedication to maintaining market integrity. For more information, stakeholders are encouraged to visit the company's website or its profile on OTC Markets.